Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients

N/ACompletedNCT04517305

Fudan University97 enrolled

Overview

To evaluate the patterns and treatment outcomes of pyrotinib plus vinorelbine in the real world.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * woman, age \> 18 years old * diagnosed with HER2 +Metastatic Breast Cancer * pyrotinib plus vinorelbine for at least one cycle, starting from 2018.05-2020.05 * available medical history Exclusion Criteria: * medical history was incomplete

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

PFS

Progression free survival

Time frame: 6 weeks

Adverse events

Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.